Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Demethylating agent" patented technology

Demethylating agents are chemical substances that can inhibit methylation, resulting in the expression of the previously hypermethylated silenced genes (see Methylation#Cancer for more detail). Cytidine analogs such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine) are the most commonly used demethylating agents. They work by inhibiting DNA methyltransferases. Both compounds have been approved in the treatment of myelodysplastic syndrome (MDS) by Food and Drug Administration (FDA) in United States. Azacitidine and decitabine are marketed as Vidaza and Dacogen respectively. Azacitidine is the first drug to be approved by FDA for treating MDS and has been given orphan drug status. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.

Methylation markers for diagnosis and treatment of ovarian cancer

InactiveUS20070087365A1Reducing and inhibiting neoplastic growthRestoring expression of the polypeptide in the cellMicrobiological testing/measurementMaterial analysisTumour suppressor geneSilencing gene
Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.
Owner:MDXHEALTH

System for biomarker discovery

The present application discloses a method for discovering a methylation marker gene for the conversion of a cell comprising: (i) comparing converted and unconverted cell gene expression content to identify a gene that is present in greater abundance in the unconverted cell; (ii) treating a converted cell with a demethylating agent and comparing its gene expression content with gene expression content of an untreated converted cell to identify a gene that is present in greater abundance in the cell treated with the demethylating agent; and (iii) identifying a gene that is common to the identified genes in steps (i) and (ii), wherein the common identified gene is the methylation marker gene.
Owner:GENOMICTREE

Method of treating cosmetic and dermatologic conditions by a demethylating agent

A method for the treatment of scars and keloids is disclosed. The treatment involves an effective dose of the demethylating agents, 5-azacytidine and 2-deoxy-5-azacytidine. The method also discloses treating skin cancer with a combination therapy comprised of UV radiation and topical application or administration of the above mentioned demethylating agents.
Owner:STRASSMANN GIDEON

Compositions and methods for epigenetic modification of nucleic acid sequences

Provided herein are pharmaceutical compositions and methods for treating disorders characterized by reduced expression of anti-oxidative stress enzymes in a subject. In one aspect, the present invention provides a method for inducing expression of anti-oxidative stress enzymes in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of a demethylating agent. The demethylating agent includes a phytochemical that induces expression of Nrf2 and Nrf2-mediated genes expressing anti-oxidative stress. Such phytochemicals include indoles, such as 3,3′-diindolylmethane (DIM) and indole-3-carbinol (I3C), and isothiocyanates, such as phenethyl isothiocyanate (PEITC) and sulforaphane (SFN).
Owner:RUTGERS THE STATE UNIV

Three-component gene expression reporting system for mammalian cells and applications of the same

Disclosed herein is a three-component gene expression reporting system for mammalian cells, the system including a first expression cassette, a second expression cassette, and a methylated polynucleotide. The three-component gene expression reporting system can be used to establish recombinant mammalian cells for use in the screening of a demethylating agent.
Owner:NATIONAL CHUNG CHENG UNIV

Method of preparing cell for transplantation

The invention describs a method of producing cells for transplantation into myocardial tissue of a mammal. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) passage culturing two times said bone marrow stem cells under conditions that maintain the characteristics of bone marrow stem cells; (c) culturing said bone marrow stem cells in cardiac specific media to differentiate into cardiomyogenic cells; and (d) collecting the cells of step (c) when about 80 to 90% of said cells are cardiomyogenic cells. The cardiomyogenic cells induced according to the method can be clinically applied more suitably than those induced using demethylating agent such as 5-azacytidine, and therefore, they provide induced bone marrow stem cells of a mammal into cardiomyocytes having high rates of cell incorporation and cell survival for treating a mammal (e.g., a human) diagnosed as having a disorder characterized by insufficient cardiac function.
Owner:ANTEROGEN

Assessing Chemotherapy Resistance of Colorectal Tumors by Determining Sparc Hypermethylation

Hypermethylation of the SPARC promoter is identified as a mechanism for repressing SPARC gene in cancer resulting in resistance to therapy. The restoration of SPARC expression with demethylating agents, such as 5-Aza-2′deoxycytidine, is shown to enhance chemosensitivity. The invention provides a mechanism of limiting the number of patients exposed to toxicity of demethylating agents by targeting its administration to the subset of patients with hypermethylation of the SPARC promoter.
Owner:TAI ISABELLA

Methylated Gene Biomarkers For Detecting Cancer

ActiveUS20070202499A1Enhanced patient survival rateImprove survival rateBiocideSugar derivativesDiagnosis cancerCancer research
The present invention includes methods diagnosising of cancer by analysis of a patient sample, particularly for the presence of a methylated SPARC nucleic acid molecule, and particularly for the diagnosis of pancreatic cancer. The invention also includes therapeutic methods for treating cancers by administering to cancers patients therapeutically effective amounts of demethylating agents.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Pharmaceutical composition of [ (3-hydroxy-4 -pyron-2-yl) methyl] -amine derivatives and DNA demethylating agents and their use as Anti-neoplastic drugs

The present invention concerns pharmaceutical compositions comprising compounds with general formula I or poly-alkyl-bis-maltolic molecules and in particular derivatives of [(3-hydroxy-4-pyron-2-yl)methyl]-amine in combination with DNA demethylating agents as anti-neoplastic drugs. In particular, for the preparation of a medicament for the treatment of neoplastic pathologies.
Owner:UNIV DEGLI STUDI DI URBINO

Method for Inducing Differentiation to Skeletal Muscle Cells

A method of efficiently and conveniently inducing differentiation from bone marrow stromal cells to skeletal muscle cells, which comprises the steps of: (a) the step of adding one or more kinds of substances selected from the group consisting of a cyclic AMP increasing agent, a cAMP analogue, and a cell differentiation stimulating factor to a culture of bone marrow stromal cells, wherein said bone marrow stromal cells are not treated with a demethylating agent, and culturing the cells; (b) the step of introducing a Notch gene and / or a Notch signaling related gene into the cells obtained in the step (a), and culturing the cells to obtain a culture of myoblasts, provided that said culture does not contain the cells introduced with the gene and non-introduced cells; and (c) the step of adding a Notch ligand to the culture of myoblasts obtained in the step (b), and culturing the cells.
Owner:KYOTO UNIV

Use of an organometallic compound as a dna-demethylating agent

Disclosed is the non-therapeutic use, as a DNA-demethylating agent, of at least one organometallic compound including an iron atom bound to two terpyridine groups. Further disclosed are method related to applying such agent as medicine.
Owner:UNIVERSITY OF LORRAINE +1

Methylation Markers for Diagnosis and Treatment of Cancers

InactiveUS20100035970A1Reducing and inhibiting neoplastic growthGrowth of cell is reduced and inhibitedBiocidePeptide/protein ingredientsCancer typeNucleotide
Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting "personalized medicine" treatments.
Owner:MDXHEALTH

Improved methods for producing mammalian pluripotent stem cell-derived endodermal cells

The present invention relates to the directed differentiation of mammalian pluripotent stem cells, especially human pluripotent stem (hPS) cells, into endodermal cells. In particular, the present invention relates to the treatment of mammalian pluripotent stem cells, especially hPS cells, with a DNA demethylating agent while undergoing differentiation into endodermal. The inventors have, as disclosed herein, found that exposing differentiating mammalian pluripotent stem cells, especially hPS cells, to a DNA demethylating agent leads to an improved morphology and improved yield of endodermal cells. The treatment with a DNA de-methylating agent also leads to a significant down-regulation of expression of the stem cell marker Oct4 and to an improved expression of endoderm specific markers, notably sox17, cxcr4 and hhex.
Owner:TAKARA BIO EURO

Method for Transdifferentiating Cells

An object of the present invention is to provide a method for transdifferentiating a mature cell without using a DNA methylating agent or a DNA demethylating agent. The present invention provides a method for transdifferentiating a finally differentiated mature cell having a first differentiation phenotype into a finally differentiated mature cell having a second differentiation phenotype that differs from the above first differentiation phenotype by changing culture conditions for the finally differentiated mature cell having the first differentiation phenotype, wherein culture conditions suitable for culturing the finally differentiated mature cell having the above first differentiation phenotype are changed to culture conditions suitable for culturing the finally differentiated mature cell having the above second differentiation phenotype.
Owner:KAZUHITO SATOMURA +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products